Novartis Shifts Clinical Trials to Emerging Markets, HB Reports

Novartis AG is shifting more of its clinical trials to emerging market regions such as Asia-Pacific, the Middle East and Africa, Handelsblatt reported, citing Novartis information.

The number of clinical trials rose to 44 percent of all of Novartis trials, not including trials of cancer drugs, the newspaper reported.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE